Corporate Development Strategy
MatriSys Bio maintains a robust pipeline of topical therapies for unmet dermatology indications. The company’s lead projects MSB-01 and MSB-03 are programs with both therapeutic and cosmetic/skin care clinical end points. Following demonstration of safety and clinical proof of efficacy of MSB-01, MatriSys Bioscience will seek commercial partnerships.
MatriSys Bio Microbiome Solution
The skin microbiome is the community of microbes, fungi and viruses and their genetic material present on the human body. The environmental niches of the skin harbor hundreds of species of harmless commensal microorganisms that maintain optimal physiological functions to control immune responses and to influence susceptibility to pathogens. The mutualistic commensal Staphylococcus epidermidis, and Staphylococcus hominis are the most abundant microbes found on healthy skin.
The skin microbiome offers unprecedented clinical benefits for a wide range of unmet medical conditions, and represents a unique opportunity for commercial development. MatriSys Bioscience is pioneering innovative therapies based on the skin microbiome. Our first S. hominis A9 based therapy is entering into phase 2a clinical trial at the end of 2016.